STOCK TITAN
  1. Home
  2. News
  3. STXS

Stereotaxis Ord - STXS STOCK NEWS

Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.

Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.

Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.

The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.

Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.

For the latest updates and more information, visit Stereotaxis.

News

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Rhea-AI Summary
Stereotaxis (STXS) to release financial results for Q4 and full year 2023 on March 4, 2024. Conference call scheduled to discuss results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
conferences earnings
-
News

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

Rhea-AI Summary
Stereotaxis (STXS) announced the successful treatment of the first patients using its Magnetic Interventional Ablation Catheter, MAGiC™, designed for minimally invasive cardiac ablation procedures. The first human procedures using the MAGiC catheter were performed at Vilnius University Hospital Santaros Klinikos in Lithuania, with eight patients treated in the first week of January. Data from the clinical trial will support the CE Mark submission of MAGiC, marking a significant milestone for Stereotaxis as they advance their comprehensive innovation strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
-
News

Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients

Rhea-AI Summary
Stereotaxis (STXS) and Baptist Health Lexington announced the successful treatment of patients using the newest advancement in the technology, the Genesis Robotic Magnetic Navigation (RMN) System. This represents a significant milestone in the field of surgical robotics for minimally invasive endovascular intervention. Baptist Health Lexington has become the first in Kentucky, and one of the first in the world, to provide the latest advancement in robotic technology to treat cardiac arrhythmias.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
News

Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Stereotaxis (NYSE: STXS) to participate in the Piper Sandler 35th Annual Healthcare Conference. David Fischel, Chairman and CEO, will present on Stereotaxis’ business and technology during a Fireside Discussion on November 30, 2023, at 1:30 pm ET. He will also be available for one-on-one meetings. The company aims to share its differentiated technology, clinical value, and growth strategy with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
-
News

Stereotaxis Reports 2023 Third Quarter Financial Results

Rhea-AI Summary
Stereotaxis (NYSE: STXS) reports Q3 2023 financial results with $7.8 million in revenue, driven by system revenue growth and a robust innovation strategy. The company remains confident in its ability to realize its innovation strategy with current resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
earnings
-
News

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

Rhea-AI Summary
Stereotaxis successfully treats first patients in the US with the integration of Abbott's EnSite™ X EP System and Stereotaxis' Robotic Magnetic Navigation System. The procedures were completed at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center. Physicians are pleased with the progress towards open interoperability and the benefits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
News

Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023

Rhea-AI Summary
Stereotaxis to release 2023 third quarter financial results on November 9th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation

Rhea-AI Summary
Stereotaxis to participate in the Society for Cardiac Robotic Navigation’s 7th Annual Meeting on October 19-20 in Washington, DC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
News

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

Rhea-AI Summary
Physicians at Heart Centre Rigshospitalet successfully treated first patients using Stereotaxis' Genesis Robotic Magnetic Navigation System, the latest and most advanced robotic technology for heart rhythm disorders. Rigshospitalet remains among the only hospitals in Denmark permitted to treat complex congenital and pediatric arrhythmias. Stereotaxis' robotic technology has successfully treated over 5,000 patients at the hospital. Positive impact expected on patient care. Stereotaxis extends partnership with Rigshospitalet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
News

Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment

Rhea-AI Summary
Stereotaxis announces successful launch of Genesis Robotic Magnetic Navigation System at Overland Park Regional Medical Center
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none

FAQ

What is the current stock price of Stereotaxis Ord (STXS)?

The current stock price of Stereotaxis Ord (STXS) is $2.06 as of February 28, 2025.

What is the market cap of Stereotaxis Ord (STXS)?

The market cap of Stereotaxis Ord (STXS) is approximately 178.8M.

What does Stereotaxis, Inc. specialize in?

Stereotaxis specializes in robotic technologies that enhance the treatment of arrhythmias and endovascular procedures.

What is the mission of Stereotaxis, Inc.?

The mission of Stereotaxis is the discovery, development, and delivery of robotic systems, instruments, and information solutions for interventional labs.

Where has Stereotaxis' technology received regulatory clearance?

Stereotaxis' technology has received regulatory clearance in the United States, European Union, Japan, Canada, China, and other regions.

What are the main revenue streams for Stereotaxis, Inc.?

The main revenue streams include systems, disposables, royalties, and subleases, with most revenue coming from disposables, services, and accessories.

Who are the key executives at Stereotaxis, Inc.?

Key executives include David L. Fischel, Chairman and CEO, and Kimberly R. Peery, Chief Financial Officer.

How does Stereotaxis' technology benefit physicians?

Stereotaxis' technology helps physicians by providing robotic precision and safety, improving lab efficiency, and enhancing procedural information integration.

How many patents does Stereotaxis hold?

Stereotaxis holds over 100 issued patents supporting its platform.

What geographic region generates the majority of Stereotaxis' revenue?

The majority of Stereotaxis' revenue is generated from the United States.

What types of procedures are enhanced by Stereotaxis' technology?

Stereotaxis' technology enhances the treatment of arrhythmias and endovascular procedures.

Where can I find more information about Stereotaxis, Inc.?

More information can be found on the company's website at www.stereotaxis.com.
Stock STXS logo
Stereotaxis Ord

NYSE:STXS

STXS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

STXS Stock Data

178.78M
70.99M
15.64%
48.76%
3.82%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
ST.LOUIS